

Summary attachment

Study title: Dabigatrans virkning på koagulationsmålinger

EudraCT : 2014-004357-13

The study was prematurely ended at 14/6-2014 after inclusion of 5 patients.

The study observed the pharmacodynamics of Dabigatran based on in vitro experiments on blood samples from patients who were started in Dabigatran treatment. Thus, no pharmacological intervention was done in the study, only blood sampling. The study was ended prematurely because it was not possible to include the relevant number of participants due to change in clinical praxis at the hospital. Instead the study was completed as an in vitro study where Dabigatran was added to the blood in vitro.

As no pharmacological intervention was done, there is no relevant safety data. There is also no meaningful data to report as no participants completed the study protocol before arresting the study.

Publication:

Pernille Just Vinholt, Christian Nielsen, Anna Cecilia Söderström, Axel Brandes, Mads Nybo. Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. *J Thromb Thrombolysis* 2017 Aug;44(2):216-222..

Pernille Just Vinholt

Department of Clinical Biochemistry and Pharmacology

Odense University Hospital